1-6 of 490 Activities
In this CME Outfitters recorded webcast, expert faculty will use real-world cases and perspectives from across the gMG care team to strengthen candidate recognition, evidence-based treatment selection, longitudinal monitoring, and shared decision-making. Education will clarify team roles and support individualized care, addressing symptom fluctuation, safety, administration preferences, treatment burden, and outcomes most meaningful to patients, including minimal symptom expression and preserved daily function.
As the fourth and final segment, this conversation brings the series full circle. After framing obesity’s heterogeneity, exploring amylin biology, and considering phenotype-guided care, it turns to the closing question: as these therapies arrive, how do we evaluate them — and whom might they help? A forward-looking, evidence-grounded finish for clinicians preparing for what comes next. All data discussed are investigational and presented as such.
In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.
As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why multiple pathways are needed and exploring the biology of amylin, it asks how clinicians might one day match patient to pathway.
In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.
In this CME Outfitters clinical clues escape room infographic, learners work through a series of interactive puzzles, unlocking each stage by applying evidence-based reasoning to real-world decision points in LA HNSCC. Along the way, participants will select and position perioperative immunotherapy and alternative evidence-based options; evaluate multidisciplinary team coordination by assessing role clarity, communication, and alignment of staging, biomarker assessment, and treatment sequencing across specialties; and recognize, differentiate, and manage treatment-related toxicities arising across perioperative care.
In the third activity of this CMEO podcast series, expert faculty will assist learners to recognize common and clinically significant extraintestinal manifestations associated with IBD, incorporate practical screening approaches into routine clinical workflows, and implement multidisciplinary care strategies for patients with systemic disease involvement.
